A new modeling study conducted by The Tufts Center for the Study of Drug Development (CSDD) finds that sponsors who employ single-source outsourcing partners, versus a multivendor development and manufacturing model, experience significant financial benefits.   The CSDD study, which compares the financial impacts of varying contract manufacturing approaches, finds that a single-source outsourcing model shortens the drug development cycle, providing sponsors with substantial financial gains fro...